During one "generation gap" quarrel with his parents young Michael cried, "I want excitement, adventure, money, and beautiful women. I'll never find it here at home, so I'm leaving. Don't try and stop me!"
With that he headed toward the door. His father rose and followed close behind.
"Didn't you hear what I said? I don't want you to try and stop me."
"Who's trying to stop you?" replied his father. "If you wait a minute, I'll go with you."
L-DopaIn 1970, L-dopa (levo-dihydroxyphenylalanine) was reported to benefit about 5% of the patients in reversing the progress of Parkinson's disease. The results of the first widescale experimental use of the drug were announced at a symposium on L-dopa at Georgetown University School of Medicine by Dr. Robert Keen, director of clinical pharmacology for Eaton Laboratories. The work also showed partial improvement in 56% of the 601 patients in this testing, which preceded approval by the U.S. Food and Drug Agency. However, side effects were found to be widespread, ranging from nausea, vomiting or appetite loss to confusion, nervousness or hallucinations. Preliminary investigations three years earlier showed the potential for the drug, when no other effective drug existed.* L-dopa entered national distribution in Sep 1970.« [Image: L-dopa molecule.] |
